Janney Montgomery Scott Downgrades Pacira Pharmaceuticals (PCRX) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices steady as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Canaccord Genuity Downgrades Pacira Pharmaceuticals (PCRX) to Hold
October 30, 2017 2:20 AM EDTCanaccord Genuity downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $33.00 (from $44.00).
Analyst Dewey Steadman says the IMS continues to disappoint and therefore steps to the sidelines noting he expects share price pressures following guidance and efforts by... More
